8-K: Inari Medical Reports 23% Revenue Growth in Second Quarter, Raises Full Year Guidance

Inari Medical announced a 23% year-over-year revenue increase for the second quarter of 2024, driven by strong adoption of its medical devices and global expansion, and raised its full-year revenue guidance.

Summary

• Inari Medical reported a revenue of $145.8 million for the second quarter of 2024, a 22.5% increase compared to $119.0 million in the same quarter of 2023.
• The company's gross profit for the quarter was $125.8 million, with a gross margin of 86.3%, slightly down from 88.4% in the prior year due to product mix and international expansion costs.
• Operating expenses increased to $148.3 million, primarily due to personnel-related costs and acquisition-related expenses.
• Inari experienced a GAAP operating loss of $22.4 million and a net loss of $31.3 million for the quarter.
• Non-GAAP operating loss was $13.2 million after excluding certain acquisition-related expenses.
• The company has raised its full-year 2024 revenue guidance to a range of $594.5 million to $604.5 million, reflecting a growth of approximately 20.5% to 22.5% over 2023.
• Inari expects to achieve sustained operating profitability in the first half of 2025.
• Cash, cash equivalents, and short-term investments totaled $110 million as of the end of the second quarter.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and increased guidance, but tempered by the operating loss and increased expenses. The company is on a growth trajectory but needs to manage costs to achieve profitability.

Positives

• Revenue increased by 22.5% year-over-year, indicating strong market adoption of Inari's products.
• The launch of VenaCore is expected to drive further growth in the DVT treatment market.
• The company's full-year revenue guidance has been increased, reflecting confidence in future performance.
• The Emerging Therapies segment showed significant growth, with a 65.6% increase in Q2 and 101.3% for the first six months of 2024.
• The company has a strong cash position of $110 million.

Negatives

• The company experienced a GAAP operating loss of $22.4 million and a net loss of $31.3 million for the quarter.
• Gross margin decreased slightly from 88.4% to 86.3% due to product mix and internationalization costs.
• Operating expenses increased significantly to $148.3 million, driven by personnel and acquisition-related costs.
• Net loss per share was $0.54 compared to a net income per share of $0.04 in the same period of the prior year.

Risks

• The company's operating expenses are increasing, which could impact profitability.
• The decrease in gross margin could be a concern if it continues in future quarters.
• The company is still operating at a loss, although they expect to reach profitability in the first half of 2025.
• The company's future performance is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

Inari expects to achieve sustained operating profitability in the first half of 2025 and anticipates continued momentum across all three growth drivers, including the release of PEERLESS data.

Management Comments

• Our second quarter performance was driven by strong adoption of our market leading solutions across our VTE, Emerging Therapies and international businesses, said Drew Hykes, CEO of Inari Medical.
• Our field team is making meaningful progress supporting our hospital customers in building VTE programs, allowing more patients to benefit from our solutions.
• We are also pleased with the progress of our new products, including the recent launch of VenaCore, as well as positive reimbursement updates benefiting LimFlow.

Industry Context

The announcement reflects a positive trend in the medical device industry, with Inari's growth driven by the increasing adoption of its innovative solutions for venous thromboembolism. The launch of VenaCore and the expansion into new markets are consistent with industry trends focused on advanced treatment options and global reach.

Comparison to Industry Standards

• Compared to companies like Penumbra, which also focuses on innovative medical devices, Inari's revenue growth of 22.5% is competitive, though Penumbra has shown higher growth rates in some quarters.
• Inari's gross margin of 86.3% is strong compared to the industry average, but the slight decrease from the previous year is a point to monitor.
• Companies like Boston Scientific and Medtronic, which have a broader portfolio, may have different financial profiles, but Inari's focus on VTE and emerging therapies allows for a more targeted comparison with smaller, specialized firms.
• The operating loss is not unusual for a growth-stage medical device company, but the path to profitability is a key metric for investors.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance, but may be concerned about the operating loss.
• Employees may benefit from the company's growth and expansion.
• Customers (hospitals and healthcare providers) will have access to new and improved medical devices.
• Suppliers may see increased demand for their products and services.
• Creditors will be monitoring the company's path to profitability.

Next Steps

• The company will host a conference call to discuss the second quarter 2024 financial results on July 30, 2024.
• The company will continue to focus on the commercial launch of VenaCore.
• The company will continue to expand its sales territories and open new accounts.
• The company will release PEERLESS data in the future.

Key Dates

Keywords

Inari Medical, VenaCore, DVT, Venous Thromboembolism, Medical Devices, Revenue Growth, Financial Results, Operating Loss, Gross Margin, Emerging Therapies